Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
A short-lived hold for Arcellx & Gilead
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
Off-the-shelf Car-T from Caribou does enough at six months
Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.
